A Phase 3 interventional study of clopidogrel (SR25990) and ticlopidine in Peripheral Arterial Disease (PAD), sponsored by Sanofi. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2012-07-17.
Sponsored by Sanofi · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing clopidogrel in Peripheral Arterial Disease — 3 open to participants now, 4 under way, none of them phase 3. Clopidogrel · Peripheral Arterial Disease.
Among the 10 studies testing clopidogrel in Peripheral Arterial Disease, this one is the 2nd largest by enrollment, is the only one that started in 2009, is one of 3 in phase 3, and was the 3rd registered.
1,377 studies on the registry are indexed under Peripheral Arterial Disease; 275 are open to participants now.
Browse Peripheral Arterial Disease studies →3 of the 10 studies testing clopidogrel in Peripheral Arterial Disease are open now, in 2 countries. Recruiting first, the newest first:
Corewell Health West · Sites in United States
Ages 45+
Massachusetts General Hospital · Sites in United States
Ages 18+
Guy's and St Thomas' NHS Foundation Trust · Sites in United Kingdom
Ages 18+
By country, each count listing its studies:
Clopidogrel: first FDA approval 1997 (PLAVIX), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 192 Peripheral Arterial Disease studies recruiting now, 138 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 431 is above the median of 70 across 927 interventional studies indexed under Peripheral Arterial Disease.
Median enrollment 205 across the 10 interventional studies. Of the 4 that completed or were terminated, 1 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 10 have an industry lead sponsor. The 8 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Sanofi has 5 studies filed under Peripheral Arterial Disease — fewer than ten, so there is no comparison to draw.
2 of the studies testing clopidogrel in Peripheral Arterial Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07613840Massachusetts General HospitalPersonalizing Thromboprophylaxis for Patients With Peripheral Artery Disease | 2027-04-29 |
| NCT07076082Corewell Health WestVascular Trial Associated Registry Pilot | 2027-10-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies testing clopidogrel in Peripheral Arterial Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary objective:
Secondary objectives:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Documented symptomatic peripheral arterial disease (one or both of the following two primary criteria must be satisfied):
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
75 mg clopidogrel once daily from Day 1 to Week 12
Drug: clopidogrel (SR25990)
200 mg ticlopidine once daily from Day 1 to Week 12
Drug: ticlopidine
oral administration (tablets)
oral administration (tablets)
Safety events of interest including clinical significant bleeding, blood disorders, hepatic dysfunction and other serious adverse drug reactions (death, hospitalization...)
Time frame: Week 12 (on treatment)
Bleeding adverse events, Serious adverse events, Overall safety
Time frame: Week 12, 52 (on treatment)
Vascular events
Time frame: Week 12, 52 (on study)
Safety events of interest (see above)
Time frame: Week 52 (on treatment)
The record gives a start of Feb 2009, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Clopidogrel